RxDoctor Payments Data

Khurram Nasir, MD

Cardiovascular Disease · New Haven, CTNPI 1861629818

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $66,089 of the $100,287 with a category attached, or 65.9%. 20 manufacturers reported payments, led by Amgen at 38.4% of the total. Reporting peaked in 2021 at $38,482 and has fallen 88.7% since, to $4,336 in 2025. Among cardiovascular disease clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$100,287in general payments, 2019–2025

Across 118 payments — averaging $849.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$39K
  • Novo Nordisk$22K
  • Novartis$11K
  • E.r. Squibb & Sons, L.L.C.$9K
  • Merck$9K
  • Regeneron Healthcare Solutions, Inc.$5K
  • plus $6K from 14 others
$132,307in research payments, 2019–2025

Across 6 payments — averaging $22,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$48K
  • Ionis Pharmaceuticals, Inc.$46K
  • Esperion Therapeutics, Inc.$32K
  • Amgen$7K

What the payments were for

  • Consulting fees$66,08966%
  • Speaking & faculty fees$28,08928%
  • Travel & lodging$2,2602%
  • Food & beverage$3,8464%
  • Education$20%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$100,287 in reported general payments places this provider in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

See all cardiovascular disease providers in Connecticut

Medicare billing

Part B allowed, 2024
$95,703
Medicare patients
3,170
Services billed
4,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab113$96,658
Praluent PenAlirocumab44$24,412
Repatha SyringeEvolocumab28$19,399
OzempicSemaglutide18$17,304
NexletolBempedoic Acid19$14,523
Ezetimibe192$6,694
Atorvastatin Calcium230$1,946
Rosuvastatin Calcium160$1,927
Losartan Potassium44$579
Lisinopril44$575
Amlodipine Besylate92$472
Pravastatin Sodium18$236
Nifedipine ErNifedipine11$223
Carvedilol16$220
Spironolactone11$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$21,643$17,30418 claims
Esperion Therapeutics, Inc.Nexletol$3,768$14,52319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 415 cardiovascular disease providers in Connecticut.

Other cardiovascular disease in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →